2-溴-4-羟基-3-硝基苯乙酮 | 5029-61-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-4-羟基-3-硝基苯乙酮
• 英文名称: α-Brom-4-hydroxy-3-nitroacetophenon
• 英文别名: 3-Nitro-4-hydroxy-phenacylbromid；Ethanone, 2-bromo-1-(4-hydroxy-3-nitrophenyl)-；2-bromo-1-(4-hydroxy-3-nitrophenyl)ethanone
• CAS: 5029-61-8
• 化学式: C₈H₆BrNO₄
• 分子量: 260.044
• InChiKey: ADFUHIYILOQDHG-UHFFFAOYSA-N

物化性质

• 熔点：
  93℃
• 沸点：
  150-155 °C(Press: 0.2 Torr)
• 密度：
  1.800±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2914700090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-Bromo-4'-Hydroxy-3'-Nitroacetophenone
: IDF00070
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 260,05 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Bromo-4'-Hydroxy-3'-Nitroacetophenone
Acute Tox. 4; Eye Irrit. 2; <= 100 %
H302, H319
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Bromo-4'-Hydroxy-3'-Nitroacetophenone
Xn, R22R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
Further information
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-4-羟基-3-硝基苯乙酮 在 硼烷四氢呋喃络合物 、 sodium methylate 、 三乙胺 、 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  一种福莫特罗重要中间体及其合成方法

  摘要：

  本发明公开了一种福莫特罗重要中间体及其合成方法，其合成方法的原料为2‑溴‑4'‑羟基苯乙酮，将原料溶解于浓硫酸中加入硝酸获得中间体I，该中间体I溶解于二氯甲烷中，加入叔丁基二甲基氯硅烷和三乙胺得中间体II，该中间体II溶解于无水四氢呋喃中，并加入(R)‑2‑甲基‑CBS‑恶唑硼烷和硼烷四氢呋喃得手性中间体III，该中间体III溶解于无水1,4‑二氧六环中，加入甲醇钠得最终产物。本发明的有益效果是，合成方法成本较低，操作过程简单，合成难度较低，产品收率较高。

  公开号：

  CN111018902A
• 作为产物：
  描述：

  2-溴-4'-羟基苯乙酮 在 三氟甲磺酸酐 、 四甲基硝酸铵 作用下， 以 二氯甲烷 为溶剂， 反应 27.0h， 以93%的产率得到2-溴-4-羟基-3-硝基苯乙酮
  参考文献：
  名称：

  亲电四烷基硝酸铵硝化。二。用硝酸四甲基铵和三氟甲磺酸酐改进无水芳族和杂芳族单硝化反应，包括选定的微波实例。

  摘要：

  提出了一种新的一锅式硝化方法，该方法采用硝酸四甲基铵和三氟甲磺酸酐在二氯甲烷中的溶液，以提供易于使用的三氟甲磺酸硝化硝化剂的来源。实现了多种芳香族和杂芳香族底物的快速选择性硝化，从而合成了几种新型有机化合物。一个明显的优点是通过水后处理除去不需要的副产物。这种非常温和的硝化作用可实现大规模合成，并获得较高的分离产物收率，而通常无需进一步纯化。这种基于硝酸四甲基铵的硝化也已应用于微波辅助条件，并概述了几种化合物的结果。

  DOI：

  10.1021/jo026202q

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS<br/>[FR] COMPOSES ET COMPOSITIONS SERVANT DE MODULATEURS PPAR
  申请人：IRM LLC

  公开号：WO2005116000A1

  公开（公告）日：2005-12-08

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

  这项发明提供了化合物，包括这些化合物的药物组合物，以及使用这些化合物来治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族的活性相关的疾病或紊乱的方法，特别是PPAR的活性。
• Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists
  作者：Si-Yun Nian、Guo-Ping Wang、Zheng-Li Jiang、Ying Xiao、Mo-Han Huang、Yi-Huan Zhou、Xiang-Duan Tan

  DOI：10.1007/s11030-018-9843-2

  日期：2019.2

  Most of reported steroidal FXR antagonists are restricted due to low potency. We described the design and synthesis of novel nonsteroidal scaffold SIPI-7623 derivatives as FXR antagonists. The most potent compound A-11 (IC50 = 7.8 ± 1.1 μM) showed better activity compared to SIPI-7623 (IC50 = 40.8 ± 1.7 μM) and guggulsterone (IC50 = 45.9 ± 1.1 μM). Docking of A-11 in FXR’s ligand-binding domain was

  大多数报道的甾体FXR拮抗剂由于药效低而受到限制。我们描述了作为FXR拮抗剂的新型非甾体支架SIPI-7623衍生物的设计和合成。 与SIPI-7623（IC 50  = 40.8±1.7μM）和古古甾酮（IC 50  = 45.9± 1.1μM）相比，最有效的化合物A-11（IC 50 = 7.8± 1.1μM）表现出更好的活性。还研究了A-11在FXR的配体结合域中的对接。
• .alpha.-Aminomethylbenzyl alcohol derivatives
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US03994974A1

  公开（公告）日：1976-11-30

  Novel .alpha.-aminomethylbenzyl alcohol derivatives, particularly .alpha.-aminoethyl-3-substituted amino-4-hydroxybenzyl alcohol derivatives. The compounds of this invention are useful as bronchodilating agents.

  小说。α-氨甲基苄醇衍生物，特别是α-氨基乙基-3-取代氨基-4-羟基苄醇衍生物。本发明的化合物可用作支气管扩张剂。
• Compounds And Compositions As Ppar Modulators
  申请人：Epple Robert

  公开号：US20070203155A1

  公开（公告）日：2007-08-30

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

  本发明提供了化合物、包含这些化合物的药物组合物以及使用这些化合物治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族的活性相关的疾病或障碍的方法，特别是与PPAR的活性相关的疾病或障碍的方法。
• TAR RNA selective targeting ruthenium(II) complexes as HIV-1 reverse transcriptase inhibitors: On exploring structure-activity relationships of multiple positions
  作者：Meng Liu、Dan-Dan Xie、Yuan-Xiao Guo、Run-Yu Zhao、Fu-Dan Liu、Hongbin Zhang、Feng Gao

  DOI：10.1016/j.jinorgbio.2024.112664

  日期：2024.10

  selective TAR RNA binder was with R = OH, R = H and R = Me. Through molecular recognition of hydrogen bonds and electrostatic attraction, they were able to firmly and selectively bind HIV-1 TAR RNA. Furthermore, they efficiently obstructed the contact between TAR RNA and Tat protein, and inhibited the reverse transcription activity of HIV-1 RT. The polypyridyl Ru(II) complexes were chemical and photo-stable

  HIV-1 逆转录酶 (RT) 抑制剂通过阻止负责病毒复制的酶的活性，在 HIV 治疗中发挥着至关重要的作用。 HIV-1 TAt 蛋白与反式激活反应 (TAR) RNA 结合并招募宿主因子来刺激 HIV-1 转录。我们创建了一个由 4 × 6 聚吡啶基 Ru(II) 复合物组成的小型文库，该复合物选择性地结合 TAR RNA，并具有针对 HIV-1 TAR RNA 的特异性靶向基团。该分子设计是通过将羟基或甲氧基引入已建立的有效 TAR 粘合剂中来进行的。通过量子化学计算从自然电荷布居和静电势分析潜在的TAR结合能力。发现关键修饰是 R 和 R 基团。最有效和选择性的 TAR RNA 结合剂是 R = OH、R = H 和 R = Me。通过氢键的分子识别和静电引力，它们能够牢固地、选择性地结合HIV-1 TAR RNA。此外，它们还有效阻碍了 TAR RNA 和 TAt 蛋白之间的接触，并抑制了